Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Eurostars project, LAMMIC, E!8972, BioLamina AB

Reference number
Coordinator BioLamina AB
Funding from Vinnova SEK 3 079 701
Project duration October 2014 - March 2017
Status Completed
Venture Eurostars

Purpose and goal

The project aimed at enabling a standardized and scalable stem cell culture for cell therapy, drug development and toxicology studies. We will develop and commercialize LN-521 coated hydrogel microcarriers and protocols for the expansion of human pluripotent stem cells (hPSC) in bioreactors. The main goals were to develop: 1. A method to scale up the production of recombinant LN-521 2. A hydrogel microcarrier coated with LN-521 adapted to support hPSC growth 3. An optimized protocol to grow hPSCs in bioreactors

Expected results and effects

The project partners were to 1) scale up production of LN-521, 2) develop GMP LN-521, 3) develop a new hydrogel microcarrier coated with LN-521 for scalable hPSC culture in bioreactors. Both GMP LN521 and the LN-521-coated hydrogel beads were going to be commercialized. We have managed to 1) scale up production, 2) develop GMP cell line expressing LN-521, 3) validate GMP LN-521 function, 4) schedule a GMP pilot run at GMP certified CMO, 5) identify a hydrogel covalently linked with low concentrations of LN-521 capable of supporting stem cell expansion.

Planned approach and implementation

The project is divided into 4 WPs: 1. Scale up LN-521 production Methods: A suspension-based cell line called CAP has been used Analysis: The CAP cells produces a functional protein in large scale 2. Development of a microcarrier coated with LN-521 Methods: Screen different hydrogels, make beads and culture hPSCs Analysis: Optimal material found. Bead manufacturing hard. Another product in pipe 3. Optimization of hPSC bioreactor culture conditions Methods: Set specs in small scale but for multiple bioreactors Analysis: Optimal protocol set 4. Pre-production Not initiated

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2014-04086

Page statistics